CStone Pharma-B (02616) Jumps Nearly 7% as ESMO Data Update Nears and Executive's Continued Share Purchases Signal Confidence in Growth

Stock News

Sep 29

According to Zhitong Finance APP, CStone Pharma-B (HKEX: 02616) rose nearly 7%, up 6.81% as of press time to HK$5.49, with turnover of HK$35.1891 million.

On the news front, the latest clinical data for the company's core asset CS2009 (a PD-1/VEGF/CTLA-4 trispecific antibody) will be disclosed in two rapid oral presentations at the European Society for Medical Oncology (ESMO) Annual Meeting to be held in October 2026.

In addition, the company's Chief Executive Officer, President of R&D, and Executive Director Yang Jianxin purchased a total of 496,000 shares of the company in the open market with personal funds between September 17 and 22, for a total consideration of more than HK$2.7 million.

It is reported that since assuming the role of Chief Executive Officer in August 2022, Dr. Yang Jianxin has cumulatively purchased more than 14.21 million shares of the company in the open market. This share purchase fully demonstrates Dr. Yang's long-term commitment to the company and his firm confidence in the company's future business prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1172233611"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1172233611\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1172233611?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-29 14:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172233611","market":"nz","top_or_hot":-1,"title":"CStone Pharma-B (02616) Jumps Nearly 7% as ESMO Data Update Nears and Executive's Continued Share Purchases Signal Confidence in Growth","media":"Stock News","content":"<p>According to Zhitong Finance APP, <b>CStone Pharma-B</b> (<b>HKEX: 02616</b>) rose nearly 7%, up 6.81% as of press time to HK$5.49, with turnover of HK$35.1891 million.<br><br>On the news front, the latest clinical data for the company's core asset CS2009 (a PD-1/VEGF/CTLA-4 trispecific antibody) will be disclosed in two rapid oral presentations at the European Society for Medical Oncology (ESMO) Annual Meeting to be held in October 2026.<br><br>In addition, the company's Chief Executive Officer, President of R&D, and Executive Director Yang Jianxin purchased a total of 496,000 shares of the company in the open market with personal funds between September 17 and 22, for a total consideration of more than HK$2.7 million.<br><br>It is reported that since assuming the role of Chief Executive Officer in August 2022, Dr. Yang Jianxin has cumulatively purchased more than 14.21 million shares of the company in the open market. This share purchase fully demonstrates Dr. Yang's long-term commitment to the company and his firm confidence in the company's future business prospects.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CStone Pharma-B (02616) Jumps Nearly 7% as ESMO Data Update Nears and Executive's Continued Share Purchases Signal Confidence in Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCStone Pharma-B (02616) Jumps Nearly 7% as ESMO Data Update Nears and Executive's Continued Share Purchases Signal Confidence in Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-29 14:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>According to Zhitong Finance APP, <b>CStone Pharma-B</b> (<b>HKEX: 02616</b>) rose nearly 7%, up 6.81% as of press time to HK$5.49, with turnover of HK$35.1891 million.<br><br>On the news front, the latest clinical data for the company's core asset CS2009 (a PD-1/VEGF/CTLA-4 trispecific antibody) will be disclosed in two rapid oral presentations at the European Society for Medical Oncology (ESMO) Annual Meeting to be held in October 2026.<br><br>In addition, the company's Chief Executive Officer, President of R&D, and Executive Director Yang Jianxin purchased a total of 496,000 shares of the company in the open market with personal funds between September 17 and 22, for a total consideration of more than HK$2.7 million.<br><br>It is reported that since assuming the role of Chief Executive Officer in August 2022, Dr. Yang Jianxin has cumulatively purchased more than 14.21 million shares of the company in the open market. This share purchase fully demonstrates Dr. Yang's long-term commitment to the company and his firm confidence in the company's future business prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VXUS","symbol_name":"国际股票ETF-Vanguard","start_time":0,"source_url":"","article_id":"1172233611","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172233611","pubTimestamp":1790662217,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"According to Zhitong Finance APP, CStone Pharma-B (HKEX: 02616) rose nearly 7%, up 6.81% as of press time to HK$5.49, with turnover of HK$35.1891 million.On the news front, the latest clinical data...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VXUS":"国际股票ETF-Vanguard","02616":"基石药业-B","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1161":"生物科技","KCAI":"KraneShares China Alpha Index ETF","BK1574":"生物医药B类股"},"translate_title":"随着 ESMO 数据更新临近以及高管持续购买股票表明对增长的信心，基石医药-B (02616) 上涨近 7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02616":1,"KCAI":1,"VXUS":1},"content_text":"According to Zhitong Finance APP, CStone Pharma-B (HKEX: 02616) rose nearly 7%, up 6.81% as of press time to HK$5.49, with turnover of HK$35.1891 million.On the news front, the latest clinical data for the company's core asset CS2009 (a PD-1/VEGF/CTLA-4 trispecific antibody) will be disclosed in two rapid oral presentations at the European Society for Medical Oncology (ESMO) Annual Meeting to be held in October 2026.In addition, the company's Chief Executive Officer, President of R&D, and Executive Director Yang Jianxin purchased a total of 496,000 shares of the company in the open market with personal funds between September 17 and 22, for a total consideration of more than HK$2.7 million.It is reported that since assuming the role of Chief Executive Officer in August 2022, Dr. Yang Jianxin has cumulatively purchased more than 14.21 million shares of the company in the open market. This share purchase fully demonstrates Dr. Yang's long-term commitment to the company and his firm confidence in the company's future business prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"executive,dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}